ClinicalTrials.gg
CompletedNCT00927589Updated Dec 10, 2015Results posted

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

A Phase 1 interventional study of carboplatin and docetaxel in Solid Cancers, sponsored by Genentech, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with HER2-positive metastatic or locally advanced inoperable cancer.

The QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. The QTcF interval is the QT interval as calculated using Fridericia's correction; the QTcB interval is the QT interval as calculated using Bazett's correction.

02

Conditions studied

  • Solid Cancers

Keywords

  • HER2+ Metastatic Cancer
  • HER2+ Locally Advanced Inoperable Cancer
  • HER2+ Solid Malignancy
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic documentation of a -positive solid in patients with or locally advanced inoperable disease
  • (LVEF) >/= 50% by multiple-gated acquisition (MUGA) scan or two-dimensional echocardiography (ECHO) \</= 42 days prior to Cycle 1, Day 1

Exclusion criteria

Exclusion Criteria:

  • History of trastuzumab treatment \</= 100 days prior to Cycle 1, Day 1
  • Pretreatment interval > 450 ms as determined by local assessment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    1

    Drug: carboplatin · Drug: docetaxel · Drug: trastuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Corrected QT Interval Using Fridericia's Correction (QTcF) at Trastuzumab Steady State

    Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Trastuzumab steady state was defined as the average of the 2 ECG measurements collected on Cycle 1 Day 8 (C1D8) and Cycle 2 Day 1 (C2D1) after the trastuzumab infusion.

    Time frame: Baseline, Cycle 1 Day 8 and Cycle 2 Day 1

  2. Maximum Observed Plasma Concentration (Cmax) of Carboplatin

    Time frame: 0 to 5 minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)

  3. Area Under the Curve From Time Zero to 6 Hours Post Infusion (AUC0-6hr) of Carboplatin

    AUC0-6hr = Area under the plasma concentration versus time curve from 0 to 6 hours post-infusion.

    Time frame: 0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)

  4. Dose-Normalized Cmax (Cmax/D) of Carboplatin

    Dose normalized Cmax is the maximum observed concentration of carboplatin in plasma normalized for different dose levels.

    Time frame: 0 to 5 minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)

  5. Geometric Mean Ratio of Cmax/D of Carboplatin

    The geometric mean ratio of Cmax of carboplatin was defined as the Cmax/D of carboplatin on Cycle 1 Day 1 (in the absence of trastuzumab) divided by Cmax/D of carboplatin on Cycle 2 Day 1 (in the presence of trastuzumab).

    Time frame: 0 to 5 minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)

  6. Dose-Normalized AUC0-6hr (AUC0-6hr/D) of Carboplatin

    AUC0-6hr/D = Area under the plasma concentration versus time curve from 0 to 6 hours post-infusion, normalized by carboplatin dose level.

    Time frame: 0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)

  7. Geometric Mean Ratio of AUC0-6hr/D of Carboplatin

    The geometric mean ratio of AUC0-6hr/D of carboplatin was defined as the AUC0-6hr/D of carboplatin on Cycle 1 Day 1 (in the absence of trastuzumab) divided by AUC0-6hr/D of carboplatin on Cycle 2 Day 1 (in the presence of trastuzumab).

    Time frame: 0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)

  8. Plasma Decay Half-Life (t1/2) of Carboplatin

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)

  9. Maximum Observed Serum Concentration (Cmax) of Trastuzumab

    Time frame: 30 (±15) minutes after the end of the infusion on Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 3 Day 1

  10. Minimum Observed Serum Trough Concentration (Cmin) of Trastuzumab

    Time frame: 15 (±15) minutes prior to the start of the trastuzumab infusion on Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 3 Day 1

Secondary outcomes

  1. Change From Baseline in Corrected QT Interval Using Bazett's Correction (QTcB) at Trastuzumab Steady State

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Bazette's formula (QTcB = QT divided by square root of RR). Trastuzumab steady state was defined as the average of the 2 ECG measurements collected on Cycle 1 Day 8 and Cycle 2 Day 1 after the trastuzumab infusion.

    Time frame: Baseline, Cycle 1 Day 8 and Cycle 2 Day 1

  2. Baseline-adjusted QTcF, QTcB, PR Interval, and QRS Duration

    For each postbaseline timepoint, a participant's corresponding baseline measure was subtracted from his or her average of the triplicate ECG measure to create a "baseline-adjusted" corresponding ECG measure for each participant at each postbaseline timepoint.

    Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)

  3. Baseline-adjusted Heart Rate

    For each postbaseline timepoint, a participant's corresponding baseline heart rate was subtracted from his or her average of the triplicate heart rate to create a "baseline-adjusted" corresponding heart rate for each participant at each postbaseline timepoint.

    Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)

  4. Number of Participants Within Each Absolute QTc Interval Category

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc less than or equal to (\<=) 450 msec, greater than (\>) 450 to \<=470 msec, \>470 to \<= 500 msec, or \>500 msec were reported.

    Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)

  5. Number of Participants With Increase From Baseline in QTc Interval

    Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of =\>30msec, 30 to \<60 msec (borderline) and \>=60 msec (prolonged) were summarized.

    Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)

  6. Number of Participants With New Abnormal U Waves on ECG

    The incidence of abnormal U-wave changes from baseline was determined based on centrally read ECG tracings comparing each of the three triplicate readings from the post baseline ECG time points to the baseline ECG reading. At each time point, if at least one of the three triplicate readings was abnormal, the participant was counted as abnormal for that ECG timepoint as follows: a large U wave, inverted U wave, or T-U fusion compared with baseline was considered an abnormal significant change from baseline.

    Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)

  7. Number of Participants With New Abnormal T Waves on ECG

    The incidence of abnormal T-wave changes from baseline was determined based on centrally read ECG tracings comparing each of the three triplicate readings from the post baseline ECG time points to the baseline ECG reading. At each time point, if at least one of the three triplicate readings was abnormal, the participant was counted as abnormal for that ECG timepoint as follows: an inverted T, flat T, or biphasic T compared with baseline was considered an abnormal significant change from baseline. Additionally, nonspecific T-wave changes from baseline were considered as abnormal nonsignificant changes from baseline. T-wave changes from baseline due to ventricular conduction or left ventricular hypertrophy strain were considered not evaluable.

    Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)

  8. Number of Participants With Abnormal Changes in PR Interval

    Criteria for abnormal changes in PR interval were defined as: =\>25 percentage (%) change from baseline, an absolute value \>200 msec, or \>=25% change from baseline and an absolute value \>200 msec.

    Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)

  9. Number of Participants With Abnormal Changes in QRS Interval

    Criteria for abnormal changes in QRS interval were defined as: \>=25% change from baseline, an absolute value \>110 msec, or \>=25% change from baseline and an absolute value \>110 msec.

    Time frame: Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)

  10. Population Pharmacokinetics of Trastuzumab

    As per planned analysis, separate population pharmacokinetic analysis results are not available for the current study as this analysis is based on pooled data from multiple studies.

    Time frame: 15 (±15) minutes prior to the start of the trastuzumab infusion, and 30 (±15) minutes after the end of the infusion on Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 3 Day 1

07

Results

Posted Dec 10, 2015

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab + Docetaxel + Carboplatin
Started59
Completed43
Not completed16
Withdrew: Death1
Withdrew: Physician decision1
Withdrew: Withdrawal by subject3
Withdrew: Adverse event2
Withdrew: Disease progression8
Withdrew: Non-compliance1

Outcome measures

PrimaryChange From Baseline in Corrected QT Interval Using Fridericia's Correction (QTcF) at Trastuzumab Steady State

Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR). Trastuzumab steady state was defined as the average of the 2 ECG measurements collected on Cycle 1 Day 8 (C1D8) and Cycle 2 Day 1 (C2D1) after the trastuzumab infusion.

Time frame:
Baseline, Cycle 1 Day 8 and Cycle 2 Day 1
Reported as:
Mean · milliseconds (msec)
Change From Baseline in Corrected QT Interval Using Fridericia's Correction (QTcF) at Trastuzumab Steady State
milliseconds (msec)Trastuzumab + Docetaxel + Carboplatin
Change From Baseline in Corrected QT Interval Using Fridericia's Correction (QTcF) at Trastuzumab Steady State-8.4 (-11.1 to -5.7)
PrimaryMaximum Observed Plasma Concentration (Cmax) of Carboplatin
Time frame:
0 to 5 minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Reported as:
Mean · Microgram per milliliter (mcg/mL)
Maximum Observed Plasma Concentration (Cmax) of Carboplatin
Microgram per milliliter (mcg/mL)Trastuzumab + Docetaxel + Carboplatin
Cycle 1 Day 1 (in absence of trastuzumab)51 ± 15.13
Cycle 2 Day 1 (in presence of trastuzumab)52 ± 16.58
PrimaryArea Under the Curve From Time Zero to 6 Hours Post Infusion (AUC0-6hr) of Carboplatin

AUC0-6hr = Area under the plasma concentration versus time curve from 0 to 6 hours post-infusion.

Time frame:
0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Reported as:
Mean · Hour*microgram/milliliter (hr*mcg/mL)
Area Under the Curve From Time Zero to 6 Hours Post Infusion (AUC0-6hr) of Carboplatin
Hour*microgram/milliliter (hr*mcg/mL)Trastuzumab + Docetaxel + Carboplatin
Cycle 1 Day 1 (in absence of trastuzumab)115 ± 28.63
Cycle 2 Day 1 (in presence of trastuzumab)123 ± 34.99
PrimaryDose-Normalized Cmax (Cmax/D) of Carboplatin

Dose normalized Cmax is the maximum observed concentration of carboplatin in plasma normalized for different dose levels.

Time frame:
0 to 5 minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Reported as:
Mean · (mcg/mL)/(min*mg/mL)
Dose-Normalized Cmax (Cmax/D) of Carboplatin
(mcg/mL)/(min*mg/mL)Trastuzumab + Docetaxel + Carboplatin
Cycle 1 Day 1 (in absence of trastuzumab)9 ± 2.52
Cycle 2 Day 1 (in presence of trastuzumab)9 ± 2.76
SecondaryChange From Baseline in Corrected QT Interval Using Bazett's Correction (QTcB) at Trastuzumab Steady State

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Bazette's formula (QTcB = QT divided by square root of RR). Trastuzumab steady state was defined as the average of the 2 ECG measurements collected on Cycle 1 Day 8 and Cycle 2 Day 1 after the trastuzumab infusion.

Time frame:
Baseline, Cycle 1 Day 8 and Cycle 2 Day 1
Reported as:
Mean · msec
Change From Baseline in Corrected QT Interval Using Bazett's Correction (QTcB) at Trastuzumab Steady State
msecTrastuzumab + Docetaxel + Carboplatin
Change From Baseline in Corrected QT Interval Using Bazett's Correction (QTcB) at Trastuzumab Steady State-5.9 (-9.2 to -2.6)
SecondaryBaseline-adjusted QTcF, QTcB, PR Interval, and QRS Duration

For each postbaseline timepoint, a participant's corresponding baseline measure was subtracted from his or her average of the triplicate ECG measure to create a "baseline-adjusted" corresponding ECG measure for each participant at each postbaseline timepoint.

Time frame:
Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Reported as:
Mean · msec
Baseline-adjusted QTcF, QTcB, PR Interval, and QRS Duration
msecTrastuzumab + Docetaxel + Carboplatin
QTcF: Cycle 1 Day 2 (30 minutes postdose) (n=49)3.5 ± 11.8
QTcF: Cycle 1 Day 8 (15 minutes predose) (n=50)-9.3 ± 12.1
QTcF: Cycle 1 Day 8 (30 minutes postdose) (n=50)-4.3 ± 12.0
QTcF: Cycle 2 Day 1 (15 minutes predose) (n=48)-15.6 ± 13.3
QTcF: Cycle 2 Day 1 (30 minutes postdose) (n=48)-13.4 ± 14.6
QTcB: Cycle 1 Day 2 (30 minutes postdose) (n=49)3.9 ± 9.7
QTcB: Cycle 1 Day 8 (15 minutes predose) (n=50)-0.8 ± 14.5
QTcB: Cycle 1 Day 8 (30 minutes postdose) (n=50)1.4 ± 14.6
QTcB: Cycle 2 Day 1 (15 minutes predose) (n=48)-13.2 ± 16.6
QTcB: Cycle 2 Day 1 (30 minutes postdose) (n=48)-14.2 ± 18.6
PR: Cycle 1 Day 2 (30 minutes postdose) (n=49)-0.1 ± 9.4
PR: Cycle 1 Day 8 (15 minutes predose) (n=50)1.4 ± 14.6
PR: Cycle 1 Day 8 (30 minutes postdose) (n=50)4.2 ± 11.8
PR: Cycle 2 Day 1 (15 minutes predose) (n=48)9.7 ± 13.1
PR: Cycle 2 Day 1 (30 minutes postdose) (n=48)13.7 ± 16.1
QRS: Cycle 1 Day 2 (30 minutes postdose) (n=49)-0.1 ± 4.0
QRS: Cycle 1 Day 8 (15 minutes predose) (n=50)-1.8 ± 5.5
QRS: Cycle 1 Day 8 (30 minutes postdose) (n=50)-1.8 ± 5.8
QRS: Cycle 2 Day 1 (15 minutes predose) (n=48)-0.5 ± 5.0
QRS: Cycle 2 Day 1 (30 minutes postdose) (n=48)-0.3 ± 6.0
SecondaryBaseline-adjusted Heart Rate

For each postbaseline timepoint, a participant's corresponding baseline heart rate was subtracted from his or her average of the triplicate heart rate to create a "baseline-adjusted" corresponding heart rate for each participant at each postbaseline timepoint.

Time frame:
Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Reported as:
Mean · beats per minute (bpm)
Baseline-adjusted Heart Rate
beats per minute (bpm)Trastuzumab + Docetaxel + Carboplatin
Cycle 1 Day 2 (30 minutes postdose) (n=49)0.5 ± 9.9
Cycle 1 Day 8 (15 minutes predose) (n=50)9.6 ± 14.9
Cycle 1 Day 8 (30 minutes postdose) (n=50)6.2 ± 13.7
Cycle 2 Day 1 (15 minutes predose) (n=48)3.1 ± 12.7
Cycle 2 Day 1 (30 minutes postdose) (n=48)-0.7 ± 12.1
SecondaryNumber of Participants Within Each Absolute QTc Interval Category

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum QTc less than or equal to (\<=) 450 msec, greater than (\>) 450 to \<=470 msec, \>470 to \<= 500 msec, or \>500 msec were reported.

Time frame:
Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Reported as:
Number · participants
Number of Participants Within Each Absolute QTc Interval Category
participantsTrastuzumab + Docetaxel + Carboplatin
QTcF<=450 msec: C1D2 30 min postdose (n=49)44
QTcF >450 to <=470 msec:C1D2 30min postdose (n=49)4
QTcF >470 to <=500 msec: C1D2 30min postdose(n=49)1
QTcF >500 msec: C1D2 30 min postdose (n=49)0
QTcF<=450 msec: C1D8 15 min predose (n=50)49
QTcF >450 to <=470 msec: C1D8 15 min predose(n=50)1
QTcF >470 to <=500 msec: C1D8 15 min predose(n=50)0
QTcF >500 msec: C1D8 15 min predose (n=50)0
QTcF<=450 msec: C1D8 30 min postdose (n=50)48
QTcF >450 to <=470 msec: C1D8 30min postdose(n=50)2
QTcF >470 to <=500 msec: C1D8 30min postdose(n=50)0
QTcF >500 msec: C1D8 30 min postdose (n=50)0
QTcF<=450 msec: C2D1 15 min predose (n=48)48
QTcF >450 to <=470 msec: C2D1 15 min predose(n=48)0
QTcF >470 to <=500 msec: C2D1 15 min predose(n=48)0
QTcF >500 msec: C2D1 15 min predose (n=48)0
QTcF<=450 msec: C2D1 30 min postdose (n=48)48
QTcF >450 to <=470 msec: C2D1 30min postdose(n=48)0
QTcF >470 to <=500 msec: C2D1 30min postdose(n=48)0
QTcF >500 msec: C2D1 30 min postdose (n=48)0
QTcB<=450 msec: C1D2 30 min postdose (n=49)36
QTcB >450 to <=470 msec:C1D2 30min postdose (n=49)10
QTcB >470 to <=500 msec: C1D2 30min postdose(n=49)2
QTcB >500 msec: C1D2 30 min postdose (n=49)1
QTcB<=450 msec: C1D8 15 min predose (n=50)41
QTcB >450 to <=470 msec: C1D8 15 min predose(n=50)7
QTcB >470 to <=500 msec: C1D8 15 min predose(n=50)2
QTcB >500 msec: C1D8 15 min predose (n=50)0
QTcB<=450 msec: C1D8 30 min postdose (n=50)39
QTcB >450 to <=470 msec: C1D8 30min postdose(n=50)9
QTcB >470 to <=500 msec: C1D8 30min postdose(n=50)2
QTcB >500 msec: C1D8 30 min postdose (n=50)0
QTcB<=450 msec: C2D1 15 min predose (n=48)43
QTcB >450 to <=470 msec: C2D1 15 min predose(n=48)4
QTcB >470 to <=500 msec: C2D1 15 min predose(n=48)1
QTcB >500 msec: C2D1 15 min predose (n=48)0
QTcB<=450 msec: C2D1 30 min postdose (n=48)43
QTcB >450 to <=470 msec: C2D1 30min postdose(n=48)5
QTcB >470 to <=500 msec: C2D1 30min postdose(n=48)0
QTcB >500 msec: C2D1 30 min postdose (n=48)0
SecondaryNumber of Participants With Increase From Baseline in QTc Interval

Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR) and by Bazette's formula (QTcB = QT divided by square root of RR). Participants with maximum increase from baseline of =\>30msec, 30 to \<60 msec (borderline) and \>=60 msec (prolonged) were summarized.

Time frame:
Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Reported as:
Number · participants
Number of Participants With Increase From Baseline in QTc Interval
participantsTrastuzumab + Docetaxel + Carboplatin
QTcF<=30 msec: C1D2 30 min postdose (n=49)49
QTcF >30 to <=60 msec:C1D2 30 min postdose (n=49)0
QTcF >60 msec: C1D2 30 min postdose (n=49)0
QTcF<=30 msec: C1D8 15 min predose (n=50)50
QTcF >30 to <=60 msec: C1D8 15 min predose (n=50)0
QTcF >60 msec: C1D8 15 min predose (n=50)0
QTcF<=30 msec: C1D8 30 min postdose (n=50)50
QTcF >30 to <=60 msec: C1D8 30 min postdose (n=50)0
QTcF >60 msec: C1D8 30 min postdose (n=50)0
QTcF<=30 msec: C2D1 15 min predose (n=48)48
QTcF >30 to <=60 msec: C2D1 15 min predose (n=48)0
QTcF >60 msec: C2D1 15 min predose (n=48)0
QTcF<=30 msec: C2D1 30 min postdose (n=48)48
QTcF >30 to <=60 msec: C2D1 30min postdose (n=48)0
QTcF >60 msec: C2D1 30 min postdose (n=48)0
QTcB<=30 msec: C1D2 30 min postdose (n=49)49
QTcB >30 to <=60 msec:C1D2 30 min postdose (n=49)0
QTcB >60 msec: C1D2 30 min postdose (n=49)0
QTcB<=30 msec: C1D8 15 min predose (n=50)50
QTcB >30 to <=60 msec: C1D8 15 min predose (n=50)0
QTcB >60 msec: C1D8 15 min predose (n=50)0
QTcB<=30 msec: C1D8 30 min postdose (n=50)49
QTcB >30 to <=60 msec: C1D8 30 min postdose (n=50)1
QTcB >60 msec: C1D8 30 min postdose (n=50)0
QTcB<=30 msec: C2D1 15 min predose (n=48)48
QTcB >30 to <=60 msec: C2D1 15 min predose (n=48)0
QTcB >60 msec: C2D1 15 min predose (n=48)0
QTcB<=30 msec: C2D1 30 min postdose (n=48)48
QTcB >30 to <=60 msec: C2D1 30min postdose (n=48)0
QTcB >60 msec: C2D1 30 min postdose (n=48)0
SecondaryNumber of Participants With New Abnormal U Waves on ECG

The incidence of abnormal U-wave changes from baseline was determined based on centrally read ECG tracings comparing each of the three triplicate readings from the post baseline ECG time points to the baseline ECG reading. At each time point, if at least one of the three triplicate readings was abnormal, the participant was counted as abnormal for that ECG timepoint as follows: a large U wave, inverted U wave, or T-U fusion compared with baseline was considered an abnormal significant change from baseline.

Time frame:
Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Reported as:
Number · participants
Number of Participants With New Abnormal U Waves on ECG
participantsTrastuzumab + Docetaxel + Carboplatin
C1D2 30 min postdose (n=49)0
C1D8 15 min predose (n=50)0
C1D8 30 min postdose (n=50)0
C2D1 15 min predose (n=48)0
C2D1 30 min postdose (n=48)0
SecondaryNumber of Participants With New Abnormal T Waves on ECG

The incidence of abnormal T-wave changes from baseline was determined based on centrally read ECG tracings comparing each of the three triplicate readings from the post baseline ECG time points to the baseline ECG reading. At each time point, if at least one of the three triplicate readings was abnormal, the participant was counted as abnormal for that ECG timepoint as follows: an inverted T, flat T, or biphasic T compared with baseline was considered an abnormal significant change from baseline. Additionally, nonspecific T-wave changes from baseline were considered as abnormal nonsignificant changes from baseline. T-wave changes from baseline due to ventricular conduction or left ventricular hypertrophy strain were considered not evaluable.

Time frame:
Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Reported as:
Number · participants
Number of Participants With New Abnormal T Waves on ECG
participantsTrastuzumab + Docetaxel + Carboplatin
C1D2 30 min postdose (n=49)0
C1D8 15 min predose (n=50)0
C1D8 30 min postdose (n=50)0
C2D1 15 min predose (n=48)0
C2D1 30 min postdose (n=48)0
SecondaryNumber of Participants With Abnormal Changes in PR Interval

Criteria for abnormal changes in PR interval were defined as: =\>25 percentage (%) change from baseline, an absolute value \>200 msec, or \>=25% change from baseline and an absolute value \>200 msec.

Time frame:
Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Reported as:
Number · participants
Number of Participants With Abnormal Changes in PR Interval
participantsTrastuzumab + Docetaxel + Carboplatin
>=25% change: C1D2 30 min postdose (n=49)0
Absolute value >200msec: C1D2 30min postdose(n=49)2
>=25%change and >200msec:C1D2 30min postdose(n=49)0
>=25% change: C1D8 15 min predose (n=50)1
Absolute value >200msec: C1D8 15 min predose(n=50)1
>=25%change and >200msec: C1D8 15min predose(n=50)1
>=25% change: C1D8 30 min postdose (n=50)0
Absolute value >200msec: C1D8 30min postdose(n=50)1
>=25%change and >200msec:C1D8 30min postdose(n=50)0
>=25% change: C2D1 15 min predose (n=48)2
Absolute value >200msec: C2D1 15 min predose(n=48)4
>=25%change and >200msec: C2D1 15min predose(n=48)1
>=25% change: C2D1 30 min postdose (n=48)2
Absolute value >200msec: C2D1 30min postdose(n=48)4
>=25%change and >200msec:C2D1 30min postdose(n=48)1
SecondaryNumber of Participants With Abnormal Changes in QRS Interval

Criteria for abnormal changes in QRS interval were defined as: \>=25% change from baseline, an absolute value \>110 msec, or \>=25% change from baseline and an absolute value \>110 msec.

Time frame:
Baseline, Cycle 1 Day 2 (30 minutes postdose), Cycle 1 Day 8 (15 minutes predose), Cycle 1 Day 8 (30 minutes postdose), Cycle 2 Day 1 (15 minutes predose), and Cycle 2 Day 1 (30 minutes postdose)
Reported as:
Number · participants
Number of Participants With Abnormal Changes in QRS Interval
participantsTrastuzumab + Docetaxel + Carboplatin
>=25% change: C1D2 30 min postdose (n=49)0
Absolute value >110msec: C1D2 30min postdose(n=49)4
>=25%change and >110msec:C1D2 30min postdose(n=49)0
>=25% change: C1D8 15 min predose (n=50)0
Absolute value >110msec: C1D8 15 min predose(n=50)4
>=25%change and >110msec: C1D8 15min predose(n=50)0
>=25% change: C1D8 30 min postdose (n=50)0
Absolute value >110msec: C1D8 30min postdose(n=50)4
>=25%change and >110msec:C1D8 30min postdose(n=500
>=25% change: C2D1 15 min predose (n=48)0
Absolute value >110msec: C2D1 15 min predose(n=48)4
>=25%change and >110msec: C2D1 15min predose(n=48)0
>=25% change: C2D1 30 min postdose (n=48)0
Absolute value >110msec: C2D1 30min postdose(n=48)4
>=25%change and >110msec:C2D1 30min postdose(n=48)0
SecondaryPopulation Pharmacokinetics of Trastuzumab

As per planned analysis, separate population pharmacokinetic analysis results are not available for the current study as this analysis is based on pooled data from multiple studies.

Time frame:
15 (±15) minutes prior to the start of the trastuzumab infusion, and 30 (±15) minutes after the end of the infusion on Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 3 Day 1

Results for this outcome have not been posted.

PrimaryGeometric Mean Ratio of Cmax/D of Carboplatin

The geometric mean ratio of Cmax of carboplatin was defined as the Cmax/D of carboplatin on Cycle 1 Day 1 (in the absence of trastuzumab) divided by Cmax/D of carboplatin on Cycle 2 Day 1 (in the presence of trastuzumab).

Time frame:
0 to 5 minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Reported as:
Geometric mean · ratio
Geometric Mean Ratio of Cmax/D of Carboplatin
ratioTrastuzumab + Docetaxel + Carboplatin
Geometric Mean Ratio of Cmax/D of Carboplatin1.02 (0.90 to 1.15)
PrimaryDose-Normalized AUC0-6hr (AUC0-6hr/D) of Carboplatin

AUC0-6hr/D = Area under the plasma concentration versus time curve from 0 to 6 hours post-infusion, normalized by carboplatin dose level.

Time frame:
0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Reported as:
Mean · (hr*mcg/mL)/(min*mg/mL)
Dose-Normalized AUC0-6hr (AUC0-6hr/D) of Carboplatin
(hr*mcg/mL)/(min*mg/mL)Trastuzumab + Docetaxel + Carboplatin
Cycle 1 Day 1 (in absence of trastuzumab)19 ± 4.77
Cycle 2 Day 1 (in presence of trastuzumab)21 ± 5.83
PrimaryGeometric Mean Ratio of AUC0-6hr/D of Carboplatin

The geometric mean ratio of AUC0-6hr/D of carboplatin was defined as the AUC0-6hr/D of carboplatin on Cycle 1 Day 1 (in the absence of trastuzumab) divided by AUC0-6hr/D of carboplatin on Cycle 2 Day 1 (in the presence of trastuzumab).

Time frame:
0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Reported as:
Geometric mean · ratio
Geometric Mean Ratio of AUC0-6hr/D of Carboplatin
ratioTrastuzumab + Docetaxel + Carboplatin
Geometric Mean Ratio of AUC0-6hr/D of Carboplatin1.07 (0.96 to 1.18)
PrimaryPlasma Decay Half-Life (t1/2) of Carboplatin

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 to 5, 60 (±5), 120 (±10), 240 (±10), and 360 (±15) minutes after end of infusion on Cycle 1 Day 1 (in absence of trastuzumab) and Cycle 2 Day 1 (in presence of trastuzumab)
Reported as:
Mean · hr
Plasma Decay Half-Life (t1/2) of Carboplatin
hrTrastuzumab + Docetaxel + Carboplatin
Cycle 1 Day 1 (in absence of trastuzumab) (n=44)2 ± 0.94
Cycle 2 Day 1 (in presence of trastuzumab) (n=43)2 ± 1.12
PrimaryMaximum Observed Serum Concentration (Cmax) of Trastuzumab
Time frame:
30 (±15) minutes after the end of the infusion on Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 3 Day 1
Reported as:
Geometric mean · mcg/mL
Maximum Observed Serum Concentration (Cmax) of Trastuzumab
mcg/mLTrastuzumab + Docetaxel + Carboplatin
Cycle 1 Day 2 (n=57)146.3 (137.3 to 155.9)
Cycle 1 Day 8 (n=51)187.1 (173.1 to 202.3)
Cycle 2 Day 1 (n=48)179.1 (166.8 to 192.4)
Cycle 3 Day 1 (n=42)181.5 (169.5 to 194.4)
PrimaryMinimum Observed Serum Trough Concentration (Cmin) of Trastuzumab
Time frame:
15 (±15) minutes prior to the start of the trastuzumab infusion on Cycle 1 Day 2, Cycle 1 Day 8, Cycle 2 Day 1, and Cycle 3 Day 1
Reported as:
Geometric mean · mcg/mL
Minimum Observed Serum Trough Concentration (Cmin) of Trastuzumab
mcg/mLTrastuzumab + Docetaxel + Carboplatin
Cycle 1 Day 2 (n=57)0.178 (0.1 to 0.2)
Cycle 1 Day 8 (n=51)38.8 (30.7 to 49.2)
Cycle 2 Day 1 (n=48)38.7 (32.9 to 45.5)
Cycle 3 Day 1 (n=42)29.7 (24.5 to 36.1)

Adverse events

Collected over Baseline up to study completion/early termination (28 to 42 days after the last administration of study treatment) (maximum treatment duration = 163 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab + Docetaxel + Carboplatin—26/58 (44.8%)56/58 (96.6%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventTrastuzumab + Docetaxel + Carboplatin
Febrile neutropeniaBlood and lymphatic system disorders5/58
Small intestinal obstructionGastrointestinal disorders3/58
PneumoniaInfections and infestations3/58
ColitisGastrointestinal disorders2/58
DehydrationMetabolism and nutrition disorders2/58
ConstipationGastrointestinal disorders1/58
DiarrhoeaGastrointestinal disorders1/58
Diverticular perforationGastrointestinal disorders1/58
Gastrointestinal haemorrhageGastrointestinal disorders1/58
HaematemesisGastrointestinal disorders1/58
Most frequent other events
Showing 10 of 81
Most frequent other events
EventTrastuzumab + Docetaxel + Carboplatin
Neutrophil count decreasedInvestigations37/58
NauseaGastrointestinal disorders34/58
Haemoglobin decreasedInvestigations33/58
FatigueGeneral disorders31/58
DiarrhoeaGastrointestinal disorders30/58
Platelet count decreasedInvestigations23/58
VomitingGastrointestinal disorders22/58
AlopeciaSkin and subcutaneous tissue disorders18/58
Decreased appetiteMetabolism and nutrition disorders17/58
White blood cell count decreasedInvestigations16/58

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)Trastuzumab + Docetaxel + Carboplatin
Mean59.0 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab + Docetaxel + Carboplatin
Female33
Male26
08

Study locations

20 sites
  • Scottsdale, Arizona 85258, United States
  • Beverly Hills, California 90211, United States
  • La Jolla, California 92093, United States
  • San Diego, California 92123, United States
  • Santa Rosa, California 95403, United States
  • Whittier, California 90603, United States
  • Miami, Florida 33136, United States
  • Wichita, Kansas 67214-3728, United States
  • Billings, Montana 59101, United States
  • Farmington, New Mexico 87401, United States
  • Bronx, New York 10461, United States
  • Memphis, Tennessee 38120, United States
  • Nashville, Tennessee 37232, United States
  • Dallas, Texas 75230, United States
  • Galveston, Texas 77555, United States
  • Houston, Texas 77024, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78229, United States
  • Temple, Texas 76508, United States
  • Seattle, Washington 98101, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2009
First posted
Jun 25, 2009
Start
Jul 2009
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Dec 10, 2015
Last update
Dec 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00927589
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Jun 25, 2009
Start date
Jul 2009
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Dec 10, 2015
Last update
Dec 10, 2015

Study contacts

Harald Weber, M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Docetaxel · Trastuzumab

Start the discussion